Prices plus VAT plus shipping costs
Ready to ship today,
Delivery time appr. 3-5 workdays
- Order number: MOX10003
FricTest® is a validated, easy to use dermographometer for diagnosing patients with symptomatic dermographism (urticaria factitia) and for measuring their trigger thresholds and disease activity. The comb-like, four-pronged design of FricTest® 4.0, the newest version of this instrument, allows for simultaneous dermal stimulation with four tips of different lengths exerting four different provocation levels, from I (the weakest) to IV (the strongest). To obtain a response, FricTest® is placed vertically so that the four tips are touching the skin, and then stroked once with moderate pressure across the width of the volar surface of the forearm (or the patient´s back) for a distance of approximately 6 centimeters. A positive response is defined by a palpable weal of ≥ 3 mm in width (the diameter of FricTest® tips) at 10 min after provocation. Positive test responses to provocation with the longest FricTest® tip provocation level IV) confirm the presence of symptomatic dermographism.
FricTest® was developed by a Charité team of scientists led by Dr. Markus Magerl and Dr. Marcus Maurer. In cooperation with Charité biomedical workshop engineers, the team had first developed several prototypes that were then tested against traditional spring-loaded one-pronged dermographometers in clinical trials. Based on the results of these studies, FricTest® 4.0 was developed together with MOXIE scientists. FricTest® 4.0 was awarded medical product status.
Quick Facts FricTest®
Purpose: Confirm diagnosis of symptomatic dermographism and determine trigger thresholds (disease activity)
Suited for: Use by health care professionals or patients
Test sites: Volar forearm or back are recommended
Test reading: 10 minutes after provocation
Test result: Positive if wheal of ≥ 3 mm in width
Młynek, A.*, Vieira dos Santos, R.*, Ardelean, E., Weller, K., Magerl, M., Church, M. K., and Maurer, M.: A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. Clin. Exp. Dermatol. 2013: 38; 360-366.
*Both authors contributed equally